Core Points - The board of directors of Fujian Cement Co., Ltd. held its 22nd meeting of the 10th session, where several key resolutions were passed [1][2][3] Group 1: Board Meeting Details - The board meeting was held on August 22, 2025, with all 9 directors present, and was chaired by Chairman Wang Zhenxing [1] - The meeting complied with relevant laws, regulations, and the company's articles of association [1] Group 2: Resolutions Passed - The board approved the proposal for the election of the 11th board of directors, nominating 9 candidates, including 3 independent director candidates [2] - The independent directors' remuneration was set at 70,000 yuan per person per year (including tax), pending shareholder approval [2] - The board approved the revision of the related party transaction management system, which will also be submitted for shareholder approval [3] - A proposal for leasing office space as a related party transaction was approved, with 7 votes in favor from non-related directors [3] - The board agreed to hold the first extraordinary general meeting of 2025 on September 15, 2025, with all 9 votes in favor [5] Group 3: Candidate Profiles - The profiles of the nominated candidates for the 11th board of directors were provided, highlighting their qualifications and experience [7][8][9][11][12][13] - All candidates meet the necessary qualifications and do not have any disqualifying relationships with the company or its major shareholders [13]

Core Points - The company held its 36th meeting of the 6th Board of Directors in 2025, where several key resolutions were passed unanimously [1][2][3] Financial Reporting - The board approved the 2025 semi-annual report and its summary, confirming compliance with relevant regulations and accuracy of the information presented [1][2] - A special report on the storage and use of raised funds for the first half of 2025 was also approved, indicating no violations in the use of these funds [2] Governance and Structural Changes - The board approved amendments to the company's articles of association to align with recent legal updates and improve operational efficiency [2][3] - The board proposed to increase its membership from six to seven by adding an independent director, ensuring that independent directors will constitute at least one-third of the board [5][6] - The board also approved the nomination of candidates for both independent and non-independent director positions for the upcoming 7th Board of Directors [6][7] Upcoming Meetings - The company scheduled its third extraordinary general meeting for 2025 on September 15 to review the resolutions passed in the recent board meeting [8]

证券代码：603855 证券简称：华荣股份 公告编号：2025-018 华荣科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 华荣科技股份有限公司（以下简称"公司"）第五届董事会第二十次会议通 知于 2025 年 8 月 15 日以电子邮件、电话形式向全体董事发出。本次会议于 2025 年 8 月 27 日在公司总部会议室以现场表决的方式召开。本次会议应到董事 8 名， 实到董事 8 名。会议由董事长胡志荣先生主持，全体高级管理人员列席了会议。 本次会议经过了适当的通知程序，会议的召集、召开和表决程序符合《中华 人民共和国公司法》等法律、法规及本公司章程的有关规定，所作决议合法有效。 二、董事会会议审议情况 本次会议审议并通过如下议案，并形成了决议： （一）、审议并通过了《2025 年半年度报告及其摘要》； 《2025 年半年度报告及其摘要》已经董事会审计委员会审议通过，并提交 董事会审议。 董事会审计委员会认为：公司 2025 年半年度报告编制符合法律、法规、公 司章程和公司内部 ...

Group 1 - The company held its 22nd meeting of the fifth board of directors on August 28, 2025, with all 7 directors present, including one participating via remote voting [2] - The board approved the 2025 semi-annual report and its summary, with a unanimous vote of 7 in favor [2] - The board also approved a special report on the use of raised funds, again with a unanimous vote of 7 in favor [2] Group 2 - The company proposed amendments to its Articles of Association, which will no longer include a supervisory board; the powers of the supervisory board will be transferred to the audit committee of the board [5] - The amendments require approval from the shareholders' meeting and must be passed by at least two-thirds of the voting rights present [5] - The company plans to revise several governance systems in accordance with relevant laws and regulations, with all proposed changes receiving unanimous approval from the board [6][7][8][9][10][11][12] Group 3 - The company is in the process of electing its sixth board of directors, with nominations for non-independent directors including Lin Jinx, Lin Jinhan, Zhao Dongping, and Liu Qin, all of whom received unanimous approval [14][15][16][17][18] - The election of independent directors is also underway, with nominees including Zhou Guolai, Zhang Xueping, and Tu Jiangnan, all receiving unanimous approval [20][21]

Group 1 - The board of directors of Robotech Co., Ltd. held its 31st meeting on August 27, 2025, to review the company's 2025 semi-annual report, which was deemed to accurately reflect the company's operational status without any false records or misleading statements [1][2] - The board unanimously approved the management and use of raised funds in compliance with relevant regulations, confirming no violations or changes that could harm shareholder interests [2][3] - A three-year shareholder return plan (2025-2027) was established to enhance transparency and protect shareholder rights, which will be submitted for approval at the upcoming extraordinary general meeting [3][4] Group 2 - The board nominated candidates for the fourth board of directors, including both non-independent and independent directors, with all candidates receiving unanimous approval from the current board [5][6][8] - The company plans to appoint a new accounting firm, Zhitong CPA, following the expiration of the contract with the previous firm, Tianjian CPA, with both firms having no objections to the change [8][9] - Amendments to the company's governance structure and articles of association were approved to align with legal requirements and improve operational standards, pending further review at the extraordinary general meeting [10][11]

证券代码：300757 证券简称：罗博特科 公告编号：2025-086 关于召开公司 2025 年第四次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 罗博特科智能科技股份有限公司（以下简称"公司"、"罗博特科"）于 2025 年 8 月 27 日召开了第三届董事会第三十一次会议，决定于 2025 年 9 月 15 日（星 期一）下午 14:00 召开公司 2025 年第四次临时股东会（以下简称"本次会议"）。 现将本次会议的有关情况通知如下： 一、召开会议的基本情况 董事会依据第三届董事会第三十一次会议决议召集本次股东会，符合《公司 法》《上市公司股东会规则》《深圳证券交易所创业板股票上市规则》等相关法 律法规及《公司章程》的规定。 罗博特科智能科技股份有限公司 （1）现场会议召开时间为：2025 年 9 月 15 日下午 14:00 开始； （2）网络投票时间为：2025 年 9 月 15 日，其中通过深圳证券交易所交易 系统投票的时间为：2025 年 9 月 15 日 9:15-9:25，9:30-11:30 和 13:00-15:00 ...

Core Viewpoint - The announcement details the upcoming election of the fifth board of directors for Shanxi Panlong Pharmaceutical Group Co., Ltd., which will consist of 9 members, including 5 non-independent directors, 3 independent directors, and 1 employee representative director [1][3]. Board Election Details - The fifth board of directors will be composed of 9 members: 5 non-independent directors, 3 independent directors, and 1 employee representative director [1]. - The board's election will be conducted through a cumulative voting system for both non-independent and independent directors [3]. Candidate Nomination - The board's nomination committee has approved the following candidates for the fifth board: - Non-independent directors: Xie Xiaolin, Wu Jie, Xie Xiaofeng, Zhang Dezhuz, Huang Jilin - Independent directors: Niu Xiaofeng, Wang Mancang, Wang Peng [2]. Candidate Qualifications - All nominated candidates have been confirmed to meet the qualifications required for directors of a listed company, in accordance with relevant laws and regulations [2]. - The number of directors who are also senior management or employee representatives will not exceed half of the total board members, and independent directors will account for at least one-third of the board [2]. Term and Transition - The term for the new board of directors will be three years, starting from the date of approval at the company's second extraordinary general meeting in 2025 [3]. - Current board members will continue to fulfill their duties until the new board is officially in place [3]. Independent Director Tenure - Independent directors cannot serve more than six consecutive years, and two current independent directors are approaching the end of their terms [3].

证券代码：002864 证券简称：盘龙药业 公告编号：2025-030 陕西盘龙药业集团股份有限公司 第四届董事会第二十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 陕西盘龙药业集团股份有限公司（以下简称"公司"）第四届董事会第二十 五次会议通知于 2025 年 8 月 16 日以邮件方式向各位董事、独立董事发出。会议 于 2025 年 8 月 26 日上午 9:00 在西安市灞桥区现代纺织产业园灞柳二路 2801 号陕西盘龙医药股份有限公司二楼会议室召开，本次会议采用现场方式召开。会 议应出席董事 9 名，实际参加表决董事 9 名。会议由公司董事长谢晓林先生召集 并主持，公司监事及高级管理人员列席了本次会议。会议的召集和召开符合《中 华人民共和国公司法》等法律、行政法规、部门规章、规范性文件及《陕西盘龙 药业集团股份有限公司章程》的有关规定。 二、董事会会议审议情况 表决结果：同意票 9 票，反对票 0 票，弃权票 0 票。 具体内容详见巨潮资讯网（http://www.cninfo.com.cn）披露的《2025 ...

Group 1 - The board of directors of Shanghai Nanfang Model Biological Technology Co., Ltd. held its 13th meeting on August 25, 2025, with all 9 directors present, including 3 independent directors [1] - The meeting discussed a request from the controlling shareholder, Tishi Consulting, to convene a temporary shareholders' meeting to review board restructuring proposals [2][3] - The proposals include adjustments to board seats, the cancellation of the supervisory board, and amendments to the company's articles of association [2][3] Group 2 - Tishi Consulting holds 35.62% of the company's shares, qualifying it to request a temporary shareholders' meeting under relevant laws and regulations [2] - The board has agreed to convene the temporary shareholders' meeting and will issue a notice within five days of the decision [6] - The voting results showed 5 votes in favor, 3 against, and 1 abstention regarding the proposals, indicating some dissent among the board members [5]

Group 1 - The company held its 34th meeting of the 8th Board of Directors on August 26, 2025, with all 9 directors present, confirming compliance with legal and procedural requirements [1][2] - The board approved a proposal to amend the company's articles of association following the completion of a share repurchase plan, which involved the repurchase of 67,850,450 shares [1][2] - The board elected several candidates for the 9th Board of Directors, including Wei Zheming, Liu Wei, Gao Tao, Liu Xiaofeng, Fu Peng, and Zhan Haitan, with unanimous support from all directors [2][3] Group 2 - The board's proposal to hold the second extraordinary general meeting of shareholders on September 12, 2025, was approved, with a registration date set for September 5, 2025 [4] - The meeting will be conducted in a hybrid format, combining on-site and online voting, at a specified location in Urumqi, Xinjiang [4] - Relevant documents, including the resolutions from the board meeting and the nomination committee's records, will be made available for review [4][5]